Pfizer's leukemia drug Bosulif wins conditional EU approval

03/29/2013 | Pharmaceutical Business Review Online

Pfizer obtained conditional approval from the European Commission to market Bosulif, or bosutinib, for adults with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitors, who can't take imatinib, nilotinib and dasatinib. The approval was based on positive data from a Phase I/II trial involving more than 500 Ph+CML patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ